Enzymes for Research, Diagnostic and Industrial Use


Cat No.
XL765 is an inhibitor of PI3K with IC50 values of 39, 113, 9, 43 and 157 nM for p110α, β, γ, δ and mTOR, respectively.
Product Overview
XL765 is a potent inhibitor of PI3Ks with IC50 values 39, 113, 43, 9 nM for p110α, β, δ, γ and 190, 908 nM for mTORC1, and mTORC2 respectively. The phosphoinositide-3 kinase (PI3K) pathway has been identified as an important target in breast cancer research. The PI3K pathway is integral to diverse cellular activities, including cellular metabolism and proliferation, survival, and differentiation. Besides, mTOR also acts as the nexus of signaling pathways regulating cell growth and proliferation. By inhibiting these targets, XL765 is thought to contribute to resistance to a variety of anticancer therapies. XL765 inhibits all four class I PI3K isoforms and mTOR with IC50 values in the nanomolar range in biochemical assays, whereas is highly selective against a panel of over 130 other human kinases. XL765 exhibits inhibition of PI3K-dependent production of the second messenger PIP3, and mTOR-dependent signaling stimulated by nutrient in cellular assays. Moreover, XL765 inhibits PI3K and mTOR-dependent phosphorylation of key components in the PI3K pathway including AKT, the substrates of AKT PRAS40 and GSK3β, p70S6K, the p70S6K substrate S6, and 4E-BP1 in diverse cancer cells. Treatment of XL765 to mice bearing xenografts of PIK3CA mutant MCF-7 breast adenocarcinoma cells or PTEN-deficient PC-3 prostate adenocarcinoma cells resulted in significant inhibition of PI3K and mTOR signaling. XL765 significantly decreased tumor growth or caused tumor shrinkage in different xenograft tumor models, including brain, lung, breast, ovarian, and prostate cancers which were correlated with inhibition of tumor cell proliferation and tumor angiogenesis, and with induction of apoptosis. However, rapamycin inhibited proliferation caused little or no induction of apoptosis. These results demonstrate that a dual inhibitor strategy, targeting both PI3K and mTOR, may offer significant advantages over specifically targeting the mTOR/Raptor complex. XL765 is currently undergoing a Phase I clinical trial in patients with solid tumors.
Molecular Weight
Store at -20°C
SAR245409; XL-765; SAR 245409; SAR-245409
39 nM; 113 nM; 9 nM; 43 nM; 157 nM
Molecular Formula
Chemical Name
Soluble in DMSO
Shipping Conditions
Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request
Download Datasheet:

Online Inquiry
*E-mail Address:
Country or Region:
*Products or Services Interested:
Project Description:
Our Products are Not Intended for Private Therapeutic Use!
*Verification Code:
Please input "enzymes"(case insensitive) as verification code.

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Sitemap  Privacy Policy  Terms and Conditions
Copyright ©2011 - 2018 Creative Enzymes.
Contact Us 45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-562-8517 1-516-512-3133
Fax: 1-631-938-8127
Distributors To view the contact information for a specific location, select the desired country:
Click unfold / close
Inquiry Basket
Delete selected Check Out
Decide to move out of the shopping cart??

Sure No, Back

Please choose product!

< Go Back
You have already added to buy this product